Your browser doesn't support javascript.
loading
HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?
Drößler, Linda; Lehmann, Clara; Töpelt, Karin; Nierhoff, Dirk; Vehreschild, Jörg J; Rybniker, Jan; Hallek, Michael; Fischer, Julia; Stormberg, Verena; Fätkenheuer, Gerd; Wieland, Ulrike; Jung, Norma.
Afiliação
  • Drößler L; Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
  • Lehmann C; Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
  • Töpelt K; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • Nierhoff D; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Vehreschild JJ; Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
  • Rybniker J; Department of Gastroenterology and Hepatology, University of Cologne, Cologne, Germany.
  • Hallek M; Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
  • Fischer J; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • Stormberg V; Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
  • Fätkenheuer G; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • Wieland U; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Jung N; Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
Infection ; 47(2): 293-300, 2019 Apr.
Article em En | MEDLINE | ID: mdl-30689161
ABSTRACT
Rituximab (RTX) has been classified as a drug associated with a high risk for hepatitis B virus (HBV) reactivation in HbsAg-negative/anti-HBc-positive patients. However, data on frequency of HBV reactivation are limited especially for RTX monotherapy. Several new recommendations for screening, monitoring and prophylactic antiviral treatment have been published recently. Here, we report the real-life experience in the management and reactivation rate of HbsAg-negative/anti-HBc-positive patients treated with RTX with or without chemotherapy from a large cohort and discuss our results in the light of updated recommendations.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativação Viral / Vírus da Hepatite B / Antirreumáticos / Rituximab / Hepatite B Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativação Viral / Vírus da Hepatite B / Antirreumáticos / Rituximab / Hepatite B Tipo de estudo: Etiology_studies / Guideline / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article